Why the study?
The study aimed to establish a practical method for assessing the tradeoff between thrombotic and bleeding risks using the ARC-HBR criteria.
Does the number of ARC-HBR criteria help assess the tradeoff between fatal bleeding and fatal MI risks in the acute phase for STEMI/NSTEMI patients?
Does the number of ARC-HBR criteria help assess the tradeoff between fatal bleeding and fatal MI risks in the acute phase for STEMI/NSTEMI patients?
The ARC-HBR criteria provide a practical tool for assessing the acute-phase tradeoff between fatal bleeding and fatal MI risks in patients with STEMI/NSTEMI to guide optimal treatment strategies.
Answers are grounded in this paper and cite their sources.
May inform acute fatal MI-bleeding tradeoff assessment via ARC-HBR in MI; leaves open prospective validation for treatment guidance.
AIMS: We aimed to establish a practical method for the assessment of tradeoff between thrombotic and bleeding risks. METHODS: We aimed to investigate the balance between bleeding risk and coronary thrombotic risk according to the number of the Academic Research Consortium for high bleeding risk (ARC-HBR) criteria in the multicenter prospective ST/non-ST elevation myocardial infarction (STEMI/NSTEMI) registry (N=12,093). Patients were divided as follows by the number of ARC-HBR criteria fulfilled: group 0, 0 major with ≤ 1 minor (N=6,792); group 1, 1 major with 0 minor (N=1,705); group 2, 0 major with ≥ 2 minors (N=790); group 3, 1 major with ≥ 1 minor (N=1,709); group 4, 2 majors with ≥ 0 minors (N=861); and group 5, ≥ 3 majors with ≥ 0 minor (N=236). We assessed the acute-phase absolute risk differences between bleeding and coronary thrombotic events in each group. RESULTS: At 7-day follow-up, all patients (groups 0-5) had a higher risk of major bleeding than that of any myocardial infarction (MI). Patients at ARC-HBR (groups 1-5) had a balanced risk between fatal MI and fatal bleeding, whereas patients at non-ARC-HBR (group 0) had a higher risk of fatal MI than that of fatal bleeding. CONCLUSIONS: All STEMI/NSTEMI patients have a relatively high risk of major bleeding as compared with the risk of any MI in the acute phase. The ARC-HBR criteria would be a practical tool for assessing the tradeoff between fatal bleeding and fatal MI risks. This practical assessment would be helpful for the optimal decision-making of appropriate treatment strategy considering the balance between bleeding and coronary thrombotic risks.
No takes yet. Share an insight, caveat, or question.
Sotomi et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: